Synonyms: APN-311 | Ch14.18 | MAb-14.18 | Unituxin®
dinutuximab is an approved drug (FDA (2015))
Compound class:
Antibody
Comment: Dinutuximab is a chimeric mouse/human monoclonal antibody targeting ganglioside-GD2.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. A patent search identifies US20140170155 [4] as the applicable patent. US20140170155 reveals APN311 as a formulation of the mouse-human chimeric anti-GD2 antibody ch14.18 recombinantly produced in Chinese hamster ovary (CHO) cells. Efficacy of the preferred antibody was determined by its cytolysis capacity in GD2-expressing cells, as determined by a complement dependent cytolysis assay. |
Classification ![]() |
|
Compound class | Antibody |
Approved drug? | Yes. FDA (2015) |
International Nonproprietary Names ![]() |
|
INN number | INN |
9754 | dinutuximab |
Synonyms ![]() |
APN-311 | Ch14.18 | MAb-14.18 | Unituxin® |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 464 |
Other databases | |
GtoPdb PubChem SID | 249565662 |
Search PubMed clinical trials | dinutuximab |
Search PubMed titles | dinutuximab |
Search PubMed titles/abstracts | dinutuximab |
Wikipedia | Dinutuximab |